Engineering a synergistic antioxidant inhibition nanoplatform to enhance oxidative damage in tumor treatment

Qianqian Zhang1, Zhen Sun1, Wenbo Sun2

  • 1State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; University of Science and Technology of China, Hefei 230026, PR China.

Acta Biomaterialia
|January 7, 2023
PubMed

Insights

This study introduces a novel nanoplatform, PPB-Ce6-Pt, designed to overcome tumor cell antioxidant defenses. It effectively depletes glutathione (GSH) and nicotinamide adenine dinucleotide phosphate (NADPH), enhancing reactive oxygen species (ROS)-mediated cancer therapy for improved tumor apoptosis and ferroptosis.

Area of Science:

  • Biomedical Engineering and Nanotechnology
  • Cancer Therapy and Drug Delivery
  • Oxidative Stress and Redox Biology

Background:

  • Tumor cells possess robust antioxidant systems, primarily involving glutathione (GSH) and nicotinamide adenine dinucleotide phosphate (NADPH), which counteract reactive oxygen species (ROS)-mediated therapies.
  • Existing strategies to deplete GSH often fail due to NADPH-dependent regeneration, limiting the efficacy of ROS-based cancer treatments.
  • Hypoxic tumor microenvironments further complicate treatment by influencing antioxidant levels and redox balance.

Purpose of the Study:

  • To engineer a nanoplatform that simultaneously depletes both GSH and NADPH to overcome tumor cell antioxidant defenses.
  • To enhance the efficacy of ROS-mediated tumor therapy, particularly in hypoxic conditions.
  • To develop a potential therapeutic agent with broad applicability using safe, readily available materials.

Main Methods:

  • Development of a nanoplatform (PPB-Ce6-Pt) integrating porous Prussian blue nanoparticles (PPB NPs) and a cisplatin prodrug [cis-Pt (IV)].
  • PPB NPs were designed with peroxidase-mimicking activity for NADPH depletion and catalase-mimicking activity for H2O2 decomposition.
  • The nanoplatform was evaluated for its ability to oxidize GSH, deplete NADPH, alleviate hypoxia, and induce oxidative damage via singlet oxygen (1O2) production.

Main Results:

  • The PPB-Ce6-Pt nanoplatform effectively reduced intracellular GSH levels and inhibited NADPH-dependent GSH regeneration.
  • Catalase-mimicking activity of PPB NPs alleviated tumor hypoxia, promoting singlet oxygen (1O2) generation by Chlorin e6 (Ce6).
  • The nanoplatform induced significant tumor cell apoptosis and ferroptosis, demonstrating enhanced oxidative damage and redox dyshomeostasis.

Conclusions:

  • The developed PPB-Ce6-Pt nanoplatform offers a synergistic strategy to attenuate intracellular antioxidant capacity for improved hypoxic tumor therapy.
  • This approach effectively overcomes tumor antioxidant defenses by targeting both GSH and NADPH, leading to enhanced ROS-mediated cell death.
  • The use of FDA-approved materials and a simple loading method positions PPB-Ce6-Pt as a promising candidate for clinical translation in cancer treatment.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K